aTYR PHARMA INC
About aTYR PHARMA INC
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $190.0K
- Net income
- -$74.1M
- Total assets
- $93.0M
- Market cap
- $46.1M
- Operating margin
- -40856.3%
- Net margin
- -39012.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $190.0K
- Operating expenses
- $77.8M
- Operating income
- -$77.6M
- Income tax
- $0
- Net income
- -$74.1M
- EPS (basic)
- $-0.80
- EPS (diluted)
- $-0.80
Balance sheet
- Total assets
- $93.0M
- Current assets
- $80.2M
- Total liabilities
- $25.7M
- Current liabilities
- $15.1M
- Shareholders’ equity
- $67.3M
Cash flow
- Operating cash flow
- -$62.0M
- Investing cash flow
- -$5.1M
- Financing cash flow
- $66.0M
- Net cash flow
- -$1.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $46.1M
- EPS (diluted)
- $-0.8
- Shares outstanding
- 98.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 7, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $74.1M in FY2025.
- Revenue declined 19% from FY2024 to FY2025.
- Trading 93% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review aTYR PHARMA INC.
Write a review
News about aTYR PHARMA INC
News & sentiment via Polygon.io
